Collectively, these findings provide evidence that among eight ASMs, N‐desmethyl clobazam, and oxcarbazepine may be transported by BCRP at clinically relevant concentrations, and targeting BCRP may potentially enhance future epilepsy treatments. The gene discussed is ABCG2; the disease is epilepsy.